Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact

Submit a comment

Air pollution and Alzheimer disease phenotype deplete esterified proresolving lipid mediator reserves in the brain
Ameer Y. Taha, Qing Shen, Yurika Otoki, Nuanyi Liang, Kelley T. Patten, Anthony E. Valenzuela, Christopher D. Wallis, Douglas J. Rowland, Abhijit J. Chaudhari, Keith J. Bein, Anthony S. Wexler, Lee-Way Jin, Brittany N. Dugger, Danielle J. Harvey, Pamela J. Lein
Ameer Y. Taha, Qing Shen, Yurika Otoki, Nuanyi Liang, Kelley T. Patten, Anthony E. Valenzuela, Christopher D. Wallis, Douglas J. Rowland, Abhijit J. Chaudhari, Keith J. Bein, Anthony S. Wexler, Lee-Way Jin, Brittany N. Dugger, Danielle J. Harvey, Pamela J. Lein
View: Text | PDF
Research Article Aging Neuroscience

Air pollution and Alzheimer disease phenotype deplete esterified proresolving lipid mediator reserves in the brain

  • Text
  • PDF
Abstract

BACKGROUND Traffic-related air pollution (TRAP) is a risk factor for Alzheimer disease (AD), where unresolved brain inflammation has been linked to deficits in the levels of free lipid mediators that enable the resolution of inflammation. It is unknown whether these deficits are due to reductions in esterified lipid pools, the main source of free bioactive proresolving lipids in the brain, and whether they are related AD pathophysiology.METHODS This unknown was tested by measuring brain esterified lipid mediators and pathogenic markers of AD in TgF344-AD and WT male and female rats exposed to filtered air or TRAP for 14 months; it was also tested in human postmortem prefrontal cortex of individuals with or without AD.RESULTS Significant reductions in proresolving lipid mediators esterified to neutral lipids and/or phospholipids were seen in AD and TRAP-exposed female rats, where levels were associated with inflammation, synaptic loss, and impaired glucose metabolism. Lower esterified proresolving lipid mediator concentrations were associated with older age in prefrontal cortex of humans with AD compared with controls.CONCLUSION Impaired resolution in AD is due to depletion of esterified proresolving lipid pools that supply the brain with free bioactive mediators involved in inflammation resolution. TRAP exposure alters the same esterified resolution pathways, reflecting convergent mechanisms underlying AD.

Authors

Ameer Y. Taha, Qing Shen, Yurika Otoki, Nuanyi Liang, Kelley T. Patten, Anthony E. Valenzuela, Christopher D. Wallis, Douglas J. Rowland, Abhijit J. Chaudhari, Keith J. Bein, Anthony S. Wexler, Lee-Way Jin, Brittany N. Dugger, Danielle J. Harvey, Pamela J. Lein

×

Guidelines

The Editorial Board will only consider comments that are deemed relevant and of interest to readers. The Journal will not post data that have not been subjected to peer review; or a comment that is essentially a reiteration of another comment.

  • Comments appear on the Journal’s website and are linked from the original article’s web page.
  • Authors are notified by email if their comments are posted.
  • The Journal reserves the right to edit comments for length and clarity.
  • No appeals will be considered.
  • Comments are not indexed in PubMed.

Specific requirements

  • Maximum length, 400 words
  • Entered as plain text or HTML
  • Author’s name and email address, to be posted with the comment
  • Declaration of all potential conflicts of interest (even if these are not ultimately posted); see the Journal’s conflict-of-interest policy
  • Comments may not include figures
This field is required
This field is required
This field is required
This field is required
This field is required
This field is required

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts